Novartis AG

SWX:NOVN Stock Report

Market Cap: CHF 176.0b

Novartis Management

Management criteria checks 2/4

Novartis' CEO is Vas Narasimhan, appointed in Feb 2018, has a tenure of 6.83 years. total yearly compensation is $15.78M, comprised of 13.7% salary and 86.3% bonuses, including company stock and options. directly owns 0.016% of the company’s shares, worth CHF28.83M. The average tenure of the management team and the board of directors is 3.3 years and 8.8 years respectively.

Key information

Vas Narasimhan

Chief executive officer

US$15.8m

Total compensation

CEO salary percentage13.7%
CEO tenure6.8yrs
CEO ownership0.02%
Management average tenure3.3yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Dec 17
Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Nov 05
We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Investors Interested In Novartis AG's (VTX:NOVN) Earnings

Oct 21
Investors Interested In Novartis AG's (VTX:NOVN) Earnings

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Sep 04
Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Novartis AG's (VTX:NOVN) Price In Tune With Earnings

Mar 12
Novartis AG's (VTX:NOVN) Price In Tune With Earnings

Novartis (VTX:NOVN) Has Announced A Dividend Of $3.30

Feb 20
Novartis (VTX:NOVN) Has Announced A Dividend Of $3.30

Is There An Opportunity With Novartis AG's (VTX:NOVN) 47% Undervaluation?

Jan 04
Is There An Opportunity With Novartis AG's (VTX:NOVN) 47% Undervaluation?

CEO Compensation Analysis

How has Vas Narasimhan's remuneration changed compared to Novartis's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$12b

Jun 30 2024n/an/a

US$10b

Mar 31 2024n/an/a

US$9b

Dec 31 2023US$16mUS$2m

US$9b

Sep 30 2023n/an/a

US$7b

Jun 30 2023n/an/a

US$7b

Mar 31 2023n/an/a

US$6b

Dec 31 2022US$12mUS$2m

US$6b

Sep 30 2022n/an/a

US$21b

Jun 30 2022n/an/a

US$22b

Mar 31 2022n/an/a

US$24b

Dec 31 2021US$12mUS$2m

US$23b

Sep 30 2021n/an/a

US$10b

Jun 30 2021n/an/a

US$9b

Mar 31 2021n/an/a

US$8b

Dec 31 2020US$12mUS$2m

US$8b

Sep 30 2020n/an/a

US$7b

Jun 30 2020n/an/a

US$7b

Mar 31 2020n/an/a

US$7b

Dec 31 2019US$12mUS$2m

US$7b

Sep 30 2019n/an/a

US$7b

Jun 30 2019n/an/a

US$7b

Mar 31 2019n/an/a

US$13b

Dec 31 2018US$10mUS$2m

US$13b

Sep 30 2018n/an/a

US$14b

Jun 30 2018n/an/a

US$14b

Mar 31 2018n/an/a

US$8b

Dec 31 2017US$5mUS$864k

US$7b

Compensation vs Market: Vas's total compensation ($USD15.78M) is above average for companies of similar size in the Swiss market ($USD4.69M).

Compensation vs Earnings: Vas's compensation has increased by more than 20% in the past year.

CEO

Vas Narasimhan (48 yo)

6.8yrs

Tenure

US$15,778,038

Compensation

Dr. Vasant Narasimhan, also known as Vas, M.D., serves as Chief Executive Officer of Novartis AG at Novartis India Ltd. Dr. Narasimhan has been Chief Executive Officer of Novartis AG since February 1, 2018...

Leadership Team

NamePositionTenureCompensationOwnership
Vasant Narasimhan
Chief Executive Officer6.8yrsUS$15.78m0.016%
CHF 28.8m
Harry Kirsch
Chief Financial Officer11.6yrsUS$7.76m0.019%
CHF 33.3m
Victor Bulto
President of US2.7yrsUS$6.13m0.0017%
CHF 3.0m
Patrick Horber
President of Internationalless than a yearUS$7.95m0.0014%
CHF 2.4m
Steffen Lang
President of Operations2.7yrsUS$4.17m0.0077%
CHF 13.5m
Paul Penepent
Head of Group Financial Reporting and Accountingno datano datano data
Sloan Simpson
Global Head of Investor Relationsless than a yearno datano data
Klaus Moosmayer
Chief Ethics6yrsUS$2.67m0.0019%
CHF 3.3m
Karen Hale
Chief Legal Officer3.6yrsUS$4.16m0.0012%
CHF 2.1m
Robert Kowalski
Chief People & Organization Officer3.3yrsUS$3.45m0.0011%
CHF 1.9m
Etienne Jousseaume
Head of Market Accessno datano datano data
Linda Armstrong
Global Head of Respiratory Developmentno datano datano data

3.3yrs

Average Tenure

56yo

Average Age

Experienced Management: NOVN's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sidonie Golombowski-Daffner
Chairperson & President of Advanced Accelerator Applicationsno datano datano data
Simon Moroney
Independent Vice Chairman of the Board4.8yrsUS$546.92k0.00030%
CHF 528.0k
Daniel Vasella
Honorary Chairmanno dataUS$3.34mno data
Bridgette Heller
Independent Non-Executive Director4.8yrsUS$511.25k0.00031%
CHF 545.6k
Joerg Reinhardt
Independent Non-Executive Chairman11.3yrsUS$4.52m0.033%
CHF 57.7m
François van Houten
Independent Non-Executive Director7.8yrsUS$469.25k0.00086%
CHF 1.5m
Ton Buechner
Independent Non-Executive Director8.8yrsUS$504.92k0.0011%
CHF 2.0m
William Winters
Independent Non-Executive Director11.9yrsUS$428.02k0.0015%
CHF 2.7m
Charles Sawyers
Independent Non-Executive Director11.9yrsUS$428.02k0.00087%
CHF 1.5m
Patrice Bula
Lead Independent Director5.8yrsUS$491.97k0.00056%
CHF 985.7k
Nancy Andrews
Independent Non-Executive Director9.8yrsUS$428.02k0.00053%
CHF 932.9k
Elizabeth Doherty
Independent Non-Executive Director8.8yrsUS$535.03k0.00074%
CHF 1.3m

8.8yrs

Average Tenure

65yo

Average Age

Experienced Board: NOVN's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 03:11
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Novartis AG is covered by 68 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
John EadeArgus Research Company
Fabrizio SpagnaAxia Financial Research